基于生理学的药理动力学建模用于预测患有脏功能障碍的癌症患者的伊马替尼布暴露:一个案例研究
Karen Rowland Yeo1, Oliver Hatley1, Ben G Small1
1Certara UK Limited, Simcyp Division, Level 2-Acero, 1 Concourse Way, Sheffield S1 2BJ, UK.
Pharmaceutics
|July 29, 2023
概括
这项研究使用了药理动力学模型来预测患有脏功能障碍的癌症患者的伊马替尼布暴露. 结果显示,α-1-酸糖蛋白水平和功能障碍严重程度会影响伊马替尼的药物暴露.
科学领域:
- 药理动力学 药理动力学
- 药物新陈代谢 药物新陈代谢
- 在瘤学瘤学.
背景情况:
- 伊马替尼布的新陈代谢涉及CYP3A4和CYP2C8,与α-1-酸糖蛋白 (AAG) 有着广泛的结合.
- 以前的生理学基础的药理动力学 (PBPK) 模型描述了伊马替尼在正常功能中的自身抑制.
- 了解功能障碍中的伊马替尼布暴露对于患者护理至关重要.
研究的目的:
- 预测不同功能障碍 (RI) 的癌症患者对伊马替尼布的暴露.
- 调查AAG水平和RI对伊马替尼的药理动学的影响.
- 支持在RI患者的临床试验设计中使用PBPK建模.
主要方法:
- 对伊马替尼布的现有PBPK模型进行了验证和调整.
- 对患有轻度至中度功能障碍的癌症患者进行了模拟.
- 调整了模型参数,以反映RI对药物代谢酶的影响.
主要成果:
- 在AAG水平和伊马替尼布暴露之间观察到正相关性.
- 对中度RI的模拟需要降低CYP3A4和CYP2C8的丰度,以匹配临床数据.
- 轻度RI不需要对酶丰度进行调整以提高模型准确度.
- AAG水平和RI程度是伊马替尼暴露变化的关键因素.
结论:
- PBPK建模准确地预测了功能障碍患者对伊马替尼的暴露.
- 无论是AAG水平还是功能障碍的程度都会显著影响伊马替尼的暴露.
- PBPK建模可以帮助将RI患者纳入临床研究,与FDA指导一致.
相关概念视频
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
61
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
61
Physiological Pharmacokinetic Models: Assumption with Protein Binding
73
Physiological models with protein binding in pharmacokinetics offer a sophisticated approach to understanding drug disposition. These models consider drug-protein interactions, enabling them to effectively predict drug concentrations in different organs and tissues. This precision aids in accurate drug dosing, providing a significant advantage over conventional models. A key process within these models is equilibration, which ensures that drug concentrations achieve a steady state within the...
73
Pharmacokinetic Models: Overview
787
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
787
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
96
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
96
Pharmacokinetic Models: Comparison and Selection Criterion
106
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
106
Renal Failure: Dose Adjustments
122
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
122


